Kirby R S
Department of Urology, St George's Hospital, London, UK.
Br J Urol. 1998 Sep;82(3):373-9. doi: 10.1046/j.1464-410x.1998.00747.x.
To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH).
Safety data from a large, multinational study were analysed retrospectively. Normotensive and hypertensive patients received escalating dosages of terazosin for 10 weeks and were maintained on 5 or 10 mg daily doses for 16 weeks (single-blind period). After the initial treatment period, only men having sufficient improvements in International Prostate Symptom Score (> or = 30%) and in peak flow rate (> or = 10%) were randomly assigned to continue terazosin or to receive placebo for 24 weeks (double-blind period).
In hypertensive patients, terazosin reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the single-blind period; these clinically significant reductions were maintained in patients receiving terazosin during the double-blind period. However, in normotensive and controlled hypertensive patients terazosin produced no clinically significant mean changes in SBP or DBP during either study period. Terazosin did not adversely affect patients receiving concomitant antihypertensive medication.
Terazosin is a safe treatment for BPH in normotensive and hypertensive men, including men who are already taking additional antihypertensive drugs.
确定特拉唑嗪在治疗良性前列腺增生（BPH）时对血压及降压治疗的影响。
对一项大型跨国研究的安全数据进行回顾性分析。血压正常和高血压患者接受递增剂量的特拉唑嗪治疗10周，并以每日5或10毫克的剂量维持治疗16周（单盲期）。在初始治疗期后，仅国际前列腺症状评分（改善≥30%）和最大尿流率（改善≥10%）有足够改善的男性被随机分配继续接受特拉唑嗪治疗或接受安慰剂治疗24周（双盲期）。
在高血压患者中，特拉唑嗪在单盲期降低了收缩压（SBP）和舒张压（DBP）；在双盲期接受特拉唑嗪治疗的患者中，这些具有临床意义的降低得以维持。然而，在血压正常和血压得到控制的高血压患者中，特拉唑嗪在两个研究期间对SBP或DBP均未产生具有临床意义的平均变化。特拉唑嗪对接受联合降压药物治疗的患者没有不良影响。
特拉唑嗪对于血压正常和高血压男性的BPH是一种安全的治疗方法，包括那些已经在服用其他降压药物的男性。
